AARD Aardvark Therapeutics, Inc.

NASDAQ
$1.26

Aardvark Therapeutics, Inc. (AARD) is expected to report earnings on February 12, 2027, after the market close. The consensus earnings estimate is a loss of $0.77 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -20.3% since its last earnings release on November 13, 2026.

Aardvark Therapeutics Missed Consensus Estimates
Friday, November 13, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · 4:55 PM ET
Earnings Whisper
-
vs ($0.77)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.